Price T Rowe Associates Inc Castle Biosciences Inc Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Castle Biosciences Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 20,860 shares of CSTL stock, worth $565,306. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,860
Previous 20,648
1.03%
Holding current value
$565,306
Previous $450,000
32.22%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding CSTL
# of Institutions
201Shares Held
24.5MCall Options Held
303KPut Options Held
30.3K-
Black Rock Inc. New York, NY3.04MShares$82.5 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.83MShares$49.5 Million0.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.75MShares$47.4 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.26MShares$34.2 Million0.61% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.26MShares$34 Million2.85% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $713M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...